Iatrogenic symptomatic hypoadrenocorticism after treatment with trilostane for hyperadrenocorticism in dogs: eight cases (2008‐2019)
Journal of Small Animal Practice · 2023
DOI: 10.1111/jsap.13594 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Small Animal Practice, 2023. Verfasst von A Lamoureux und 4 weiteren Autor:innen. Beteiligte Einrichtung: Département des animaux de compagnie de loisir et de sport, Université de Lyon, VetAgro Sup, Campus vétérinaire de Lyon, Marcy L'Etoile, 69280, Franc…. Hauptthemen laut MEDLINE: Dog Diseases, Adrenocortical Hyperfunction, Adrenal Insufficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Trilostane is the medical treatment of choice for hyperadrenocorticism. Iatrogenic hypoadrenocorticism is thought to be rare, with most cases being transient and only a few cases of permanent hypoadrenocorticism have been reported. This study reports findings from eight cases of iatrogenic hypoadrenocorticism and examines the presence of concurrent diseases at the time of diagnosis. Materials and Methods Medical records of dogs treated for hyperadrenocorticism with trilostane since 2008 were reviewed, and cases of clinical iatrogenic hypoadrenocorticism were extracted. Cases were considered permanent if long‐term replacement therapy was required.
Results
Eight dogs met the inclusion criteria. The time between the beginning of trilostane treatment and the diagnosis of hypoadrenocorticism ranged from 4 days to 13 months, and the dosage of trilostane ranged between 1 and 8 mg/kg/day. Six dogs had a suspicion of concurrent disease at the time of hypoadrenocorticism diagnosis. The trilostane dose was decreased in two dogs; trilostane was withdrawn in one case without further relapse of hyperadrenocorticism; and glucocorticoids with or without mineralocorticoid supplementation were prescribed in five dogs. Two of these five dogs were lost to follow‐up, and the other three had a diagnosis of permanent hypoadrenocorticism. Adrenal gland ultrasonography in these three dogs showed a progressive reduction in gland sizes with heterogeneous echogenicity. Clinical Significance Iatrogenic hypoadrenocorticism is a rare but potentially life‐threatening complication of trilostane treatment in dogs with hyperadrenocorticism. The occurrence of a concurrent disease might trigger the development of clinical signs of hypoadrenocorticism in previously subclinical dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Département des animaux de compagnie de loisir et de sport, Université de Lyon, VetAgro Sup, Campus vétérinaire de Lyon, Marcy L'Etoile, 69280, France.
ORCID-Profile: A Lamoureux
Zitieren
APA
Lamoureux, A., Cadoré, J. L., Hugonnard, M., Chabanne, L., & Krafft, E. (2023). Iatrogenic symptomatic hypoadrenocorticism after treatment with trilostane for hyperadrenocorticism in dogs: eight cases (2008‐2019). Journal of Small Animal Practice. https://doi.org/10.1111/jsap.13594
Vancouver
Lamoureux A, Cadoré JL, Hugonnard M, Chabanne L, Krafft E. Iatrogenic symptomatic hypoadrenocorticism after treatment with trilostane for hyperadrenocorticism in dogs: eight cases (2008‐2019). Journal of Small Animal Practice. 2023. doi:10.1111/jsap.13594
BibTeX
@article{Lamoureux2023,
author = {Lamoureux, A and Cadoré, J L and Hugonnard, M and Chabanne, L and Krafft, E},
title = {Iatrogenic symptomatic hypoadrenocorticism after treatment with trilostane for hyperadrenocorticism in dogs: eight cases (2008‐2019)},
journal = {Journal of Small Animal Practice},
year = {2023},
doi = {10.1111/jsap.13594}
}
EUVIMED